Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants

The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial

The decision to treat patent ductus arteriosus in preterm infants, varies from a conservative, medical or immediate surgical treatment; although, at present, there is some controversy about this decision. This study aims to determine the efficacy and safety of surgical versus pharmacological treatment of patent ductus arteriosus in preterm infants.

Studienübersicht

Detaillierte Beschreibung

The ductus arteriosus varies in length, diameter and morphology. The duct closure occurs in two stages: the first one or functional closure; the second or anatomical closure. This condition is associated with other heart diseases, which modify the natural history and require individualized treatment. Treatment varies from conservative, pharmacological or surgical treatment, and there are many controversies regarding the treatment decision. And aims of the closure, is to decrease the likelihood of irreversible pulmonary vascular disease, reduce associated morbidity and mortality. The role of prostaglandin E2 is the permeability of the conduit, by which is indicated the use of cyclooxygenase inhibitors for closure (indomethacin and ibuprofen). In various research studies many factors associated with failure of pharmacological treatment (gestational age, antenatal indomethacin less than 48 hours before delivery, use of high frequency ventilation) are reported, therefore, there is an alternative treatment which is surgical closure. In the pharmacological treatment of ductus arteriosus persistent it should be individualized according to gestational age, respiratory condition and size of the newborn. With early drug treatment can achieve closure of patent ductus arteriosus in up to 90% of cases, while the late treatment between 50-65%. However, it is reported that after treatment with indomethacin, reopening occurs, two doses are recommended more after the first, in addition to its side effects, contraindications and complications. As well, ibuprofen contraindications. So the closure of the ductus arteriosus persistent may be performed by hemodynamics and surgical closure (standard left thoracotomy or thoracoscopic technique). There are specific indications for surgical treatment (no response to two cycles of medical treatment in newborns with less than 1000 gr weight in which I fail one indomethacin, absolute contraindications to it, with significant hemodynamic repercussions. With surgical treatment before the third week of life minimizing morbidity. it is reported by many authors that complications are rare and mortality is associated with other complications of prematurity. So Surgical treatment is considered as an alternative because of its low incidence of complications, mortality and lower cost, plus a total occlusion between 94-100% Because of this, the treatment of patent ductus arteriosus in preterm infants, ranging from conservative treatment, medical or surgical, and currently there is much controversy in the treatment decision.

This study aims to determine the efficacy and safety of surgical versus pharmacological treatment for the permanent closure of the patent ductus arteriosus in preterm infants.

Methods: Is open label randomized controlled the clinical trial with: 1) experimental group assigned to surgical treatment; 2) control group assigned to pharmacological treatment, for closure of patent ductus arteriosus.

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

40

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Esaú Luis Nieto, Pediatrician
  • Telefonnummer: 5564787736
  • E-Mail: dresauln@gmail.com

Studienorte

      • Distrito Federal, Mexiko, 04477
        • Rekrutierung
        • Hospital General Naval de Alta Especialidad
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Tag bis 1 Monat (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Preterm infants
  • Preterm infants hospitalized in the Neonatal Intensive Care Unit with a diagnosis of patent ductus arteriosus

Exclusion Criteria:

  • Preterm infants with supportive treatment and / or drug prior to patent ductus arteriosus in another medical unit
  • Preterm infants diagnosed with heart disease associated complex.
  • Preterm infants with associated disease (not hemodynamic or cardiovascular) and its impact on his state of health prior to drug treatment and / or surgery
  • Preterm infants with contraindications to pharmacological and / or surgery treatment
  • Newborns diagnosed with patent ductus arteriosus but with incomplete medical records

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Surgical treatment
Implement surgical treatment for closure of patent ductus arteriosus
Standard left thoracotomy
Andere Namen:
  • Chirurgie
Aktiver Komparator: Control group

- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg

- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg

- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg

- Indomethacin:

Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:

Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:

Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:

First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg

- Acetaminophen

Administer 1 full cycle, in the first fourteen days of life in preterm infants:

Acetaminophen 15 mg/kg every 6 hours for 3 days

Andere Namen:
  • Pharmakologisch

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Success rate of closure patent ductus arteriosus
Zeitfenster: 10 days after treatment
Tracking each patient for 10 days after treatment (surgical / pharmacological) to verify success rate of closure of patent ductus arteriosus (Failure of ductal closure ) (%)
10 days after treatment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time from diagnosis to resolution of patent ductus arteriosus
Zeitfenster: 1 month
To compare the time from diagnosis to resolution of patent ductus arteriosus (days)
1 month
Time from start of treatment until resolution
Zeitfenster: 10 days after treatment
To compare the time from start of treatment until resolution of patent ductus arteriosus (days)
10 days after treatment
Time limitation of family contact
Zeitfenster: 1 month
To compare the time limitation of family contact from diagnosis to hospital discharge of newborns of patent ductus arteriosus (days)
1 month
Adverse effects and complications of treatment
Zeitfenster: 10 days
Describe the type of adverse effects and / or complications (Chronic lung disease , Intraventricular haemorrhage, Creatinine level > 1.8 mg/dl, Pneumothorax , Sepsis, Necrotising enterocolitis, Retinopathy of prematurity, Other bleeding) and the frequency of the two study groups (yes / no)
10 days
Death before discharge
Zeitfenster: 1 month
To compare related mortality among surgical and pharmacological treatment (%)
1 month
Time of mechanical ventilatory support, parenteral nutrition, fasting, supplementary O2
Zeitfenster: 1 month
To compare the duration of mechanical ventilatory support, parenteral nutrition, fasting, supplementary O2 (days).
1 month
Anatomy of the ductus arteriosus persistent
Zeitfenster: 1 month
Describe the size of the ductus arteriosus (mm)
1 month
Gestational age at birth
Zeitfenster: At birth
Describe the gestational age of neonates (weeks)
At birth
Apgar
Zeitfenster: At birth
Describe the Apgar score of newborns (3-9)
At birth
Blood flow
Zeitfenster: 1 month
Describe the direction of blood flow of the ductus arteriosus (left-right, left-right, two-way)
1 month
Gradient of the ductus arteriosus
Zeitfenster: 1 month
Describe the gradient of the ductus arteriosus (mmHg).
1 month

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Esaú Luis Nieto, Pediatrician, Hospital General Naval de Alta Especialidad - Escuela Medico Naval

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Oktober 2015

Primärer Abschluss (Voraussichtlich)

1. April 2016

Studienabschluss (Voraussichtlich)

1. Oktober 2017

Studienanmeldedaten

Zuerst eingereicht

8. November 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. November 2015

Zuerst gepostet (Schätzen)

11. November 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

17. November 2015

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2015

Zuletzt verifiziert

1. November 2015

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Anhaltender Ductus Arteriosus

Klinische Studien zur Surgical treatment

3
Abonnieren